Xilio Therapeutics (XLO) Non-Current Assets (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Non-Current Assets data on file, last reported at $9.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 11.75% year-over-year to $9.3 million; the trailing twelve-month figure through Mar 2026 stood at $38.6 million (down 13.31% YoY), and the FY2025 full-year result was $9.7 million, down 10.91% from the prior year.
• Non-Current Assets retreated to $9.3 million in Q1 2026, from $9.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $15.3 million in Q1 2022 to a low of $9.3 million in Q1 2026.
• A 5-year average of $12.4 million and a median of $12.8 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets decreased 0.35% in 2022 and fell 21.66% in 2025, its largest moves.
• Tracing XLO's Non-Current Assets over 5 years: stood at $14.7 million in 2022, then fell by 12.75% to $12.8 million in 2023, then declined by 15.3% to $10.8 million in 2024, then fell by 10.91% to $9.7 million in 2025, then decreased by 3.91% to $9.3 million in 2026.
• Business Quant data shows XLO's Non-Current Assets at $9.3 million in Q1 2026, $9.7 million in Q4 2025, and $9.6 million in Q3 2025.